While much of the focus on AstraZeneca PLC's first-quarter figures was on its COVID-19 products Vaxzevria and Evusheld, the drug that caught the eye was Farxiga, hitting the $1bn sales mark and exceeding analyst forecasts by some distance.
Speaking to Scrip as AstraZeneca unveiled a healthy set of financials for the first quarter which saw sales jump 56%...







